www.aardvarktherapeutics.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $129.13MM
Aardvark Therapeutics is a biotechnology company that aims to develop treatments for metabolic and inflammatory diseases. Specifically, the company focuses on its small molecule therapeutics that have a mission to help activate the gut-to-brain signaling pathways related to hunger and appetite suppression. The company’s main product candidate ARD-101 is an oral compound that aims to act as a bitter taste receptor with the goal of reducing appetite and promoting weight loss. Aardvark Therapeutics was founded in 2017 by Andreas Niethammer and Tien Lee and is headquartered in San Diego, CA.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Aardvark Therapeutics.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.